KDM1A, PHF13 and miR6859 epigenetic regulators were selected from those 200 genes that showed the greatest difference in expression levels in the case of comparing ruxolitinib-treated and untreated CLL cells. This evidence concerns the gene PHF13 and B-cell chronic lymphocytic leukemia.